Enjoy complimentary customisation on priority with our Enterprise License!
Based on Technavio's market sizing methodology, the gynecological cancers therapeutics market size is predicted to surge to USD 14.22 billion from 2021 to 2026 at a CAGR of 14.67%.
This gynecological cancers therapeutics market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. The gynecological cancers therapeutics market report also offers information on several market vendors, including AbbVie Inc., Amgen Inc., AstraZeneca Plc, Becton Dickinson and Co., Biocon Ltd., Bristol Myers Squibb Co., Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ImmunoGen Inc., Johnson and Johnson, Karyopharm Therapeutics Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Siemens Healthcare GmbH, and Teva Pharmaceutical Industries Ltd. among others.
This report further entails gynecological cancers therapeutics market segmentations, including:
Download the Free Report Sample to Unlock the Gynecological Cancers Therapeutics Market Size for the Forecast Period and Other Important Statistics
"The rise in the incidence of gynecological cancers in countries such as the US and Canada is driving market growth in North America, it is estimated that around 14,100 women living in the US will be diagnosed with cervical cancer and more than 4,280 women may die from cervical cancer in 2022 "
The increasing incidence of gynecological cancers is notably driving the gynecological cancers therapeutics market growth, although factors such as the high cost of treatment may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the gynecological cancers therapeutics industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Gynecological Cancers Therapeutics Market Driver
The increasing incidence of gynecological cancers is one of the key drivers contributing to the gynecological cancers therapeutics market growth. One of the most frequently diagnosed cancers in women after breast cancer is gynecological cancers. As per the CDC, in the US, all women have a high risk of developing gynecological cancers, which increase with age. It has been estimated that each year in the US, about 71,500 new cases of gynecological cancers are diagnosed, and about 26,500 deaths are attributed to gynecological cancers, including cervical, ovarian, uterine, vaginal, and vulvar cancers. Moreover, the increasing incidence can be attributed to risk factors such as obesity, viral infections, smoking, and immune system deficiency. Such an increasing incidence of gynecological cancers will drive the gynecological cancers therapeutics market growth during the forecast period.
Key Gynecological Cancers Therapeutics Market Trend
The emergence of novel therapies is one of the key gynecological cancers therapeutics market trends supporting the market growth. There are several novel hormonal therapies emerging to prevent the recurrence of gynecological cancers such as recurrent ovarian cancer. For instance, MEK162 from Array BioPharma is in Phase III of clinical trials for the treatment of low-grade serous ovarian, fallopian tube, and peritoneal cancer. Similarly, Adaptimmune Therapeutics plc is developing an adoptive cell immunotherapy ADP-A2M4, which utilizes CAR-engineered T-cells to target melanoma-associated antigen MAGE-A4 in patients with ovarian cancer. Such emerging novel therapies will drive the growth of the global gynecological cancers therapeutics market during the forecast period.
Key Gynecological Cancers Therapeutics Market Challenge
The high cost of treatment is one of the factors challenging the gynecological cancers therapeutics market growth. Primarily, gynecological cancers require long-term treatment, which increases the overall treatment cost and the economic burden on patients. Apart from the long duration of the treatment, the therapies used, especially targeted therapies, are very expensive. Moreover, emerging targeted therapies such as monoclonal antibodies are also extremely expensive, and their use contributes to the financial burden on people with gynecological cancers. Also, the cost of these treatments is high because of the advanced procedures involved in the development of monoclonal antibodies. Such high costs associated with the treatment will challenge the gynecological cancers therapeutics market growth during the forecast period.
This gynecological cancers therapeutics market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global gynecological cancer therapeutics market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the gynecological cancers therapeutics market during the forecast period.
The parent global pharmaceuticals market covers products and companies engaged in the research and development (R and D) or production of generic, non-generic, and veterinary drugs. Technavio calculates the global healthcare market size based on the combined revenue generated by manufacturers/providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Growth in the global pharmaceuticals market will be driven by the following factors: Increasing life expectancy: The proportion of the global population over the age of 60 years is forecast to increase significantly. By 2050, nearly one-fourth of the US population is projected to be over 60 years, while Europe is likely to reach a similar population ratio by 2030.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the gynecological cancers therapeutics market encompasses successful business strategies deployed by the key vendors. The gynecological cancers therapeutics market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The gynecological cancers therapeutics market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the gynecological cancers therapeutics market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the gynecological cancers therapeutics market in North America. Market growth in this region will be faster than the growth of the market in Rest of World (ROW).
The availability of favorable reimbursement schemes will facilitate the gynecological cancers therapeutics market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 outbreak temporarily impacted the growth of the regional market in 2020-2021. However, the initiation of COVID-19 vaccination drives from December 2020 and the subsequent lifting of lockdown restrictions led to the gradual resumption of operations at pharmaceutical manufacturing and logistics units, which helped in easing R&D-related constraints. Thus, the gradually improving situation from the impact of the COVID-19 outbreak in North America is expected to increase the demand for gynecological cancers therapeutics during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The gynecological cancers therapeutics market share growth by the uterine cancer segment will be significant during the forecast period. Uterine cancer begins in the layer of cells that form the inner lining of the uterus. There are different types of uterine cancer, and the most common one is endometrial cancer, which originates in the endometrium or the inner lining of the uterus. The treatment of uterine cancer involves the surgical removal of the uterus (hysterectomy) followed by radiation and chemotherapy. Moreover, uterine cancer is reported to be the fourth most common cancer among women in the US. Thus, the increasing prevalence of uterine cancer will drive the gynecological cancers therapeutics market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the gynecological cancers therapeutics market size and actionable market insights on post COVID-19 impact on each segment.
|
Gynecological Cancers Therapeutics Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2021 |
|
Forecast period |
2022-2026 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 14.67% |
|
Market growth 2022-2026 |
$ 14.22 billion |
|
Market structure |
Fragmented |
|
YoY growth (%) |
10.4 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 37% |
|
Key consumer countries |
US, Canada, Germany, UK, and China |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Amgen Inc., AstraZeneca Plc, Becton Dickinson and Co., Biocon Ltd., Bristol Myers Squibb Co., Clovis Oncology Inc., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, ImmunoGen Inc., Johnson and Johnson, Karyopharm Therapeutics Inc., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Siemens Healthcare GmbH, and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Get the report (PDF) sent to your email within minutes.
